ProCE Banner Activity

Phase II Trial of Neoadjuvant Osimertinib in Stage I-IIIA EGFR-Mutated NSCLC

Conference Coverage
Slideset

In this small study, preliminary results with up to 2 months of neoadjuvant osimertinib demonstrated a major pathologic response in 15% of patients with surgically resectable, EGFR-mutated NSCLC.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure